Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Overwhelming evidence spanning three decades has consistently shown that coronary artery disease is a major cause of morbidity and mortality in Systemic Lupus Erythematosus. Traditionally this was explained by abnormalities of the lipid profile induced by prolonged steroid treatment. Subsequently, antiphospholipid antibodies were presented as an additional cardiovascular risk factor. Recently, antibodies towards high-density lipoprotein and antiapolipoprotein A-I have been identified. These, together with anti-beta2 glycoprotein-1, interfere with the major antioxidant defence of patients with SLE and with primary antiphospholiqid syndrome exposing them to the atherogenic potential of enhanced oxidative stress. The present review discusses how the latter auto-antibodies, together with abnormalities of their target lipid auto-antigens, could enhance the risk of atherosclerosis in SLE and APS.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalImmunobiology
Volume207
Issue number1
DOIs
Publication statusPublished - 2003

Fingerprint

Antiphospholipid Syndrome
Systemic Lupus Erythematosus
Atherosclerosis
Oxidative Stress
Lipids
Antiphospholipid Antibodies
Antibodies
HDL Lipoproteins
Coronary Artery Disease
Glycoproteins
Antioxidants
Steroids
Morbidity
Antigens
Mortality
Therapeutics
lipoprotein A-I

Cite this

@article{7009aa815fc24621b9b988e5290d0594,
title = "Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome",
abstract = "Overwhelming evidence spanning three decades has consistently shown that coronary artery disease is a major cause of morbidity and mortality in Systemic Lupus Erythematosus. Traditionally this was explained by abnormalities of the lipid profile induced by prolonged steroid treatment. Subsequently, antiphospholipid antibodies were presented as an additional cardiovascular risk factor. Recently, antibodies towards high-density lipoprotein and antiapolipoprotein A-I have been identified. These, together with anti-beta2 glycoprotein-1, interfere with the major antioxidant defence of patients with SLE and with primary antiphospholiqid syndrome exposing them to the atherogenic potential of enhanced oxidative stress. The present review discusses how the latter auto-antibodies, together with abnormalities of their target lipid auto-antigens, could enhance the risk of atherosclerosis in SLE and APS.",
author = "Alves, {Jose D.} and Ames, {Paul R.J.}",
year = "2003",
doi = "10.1078/0171-2985-00215",
language = "English",
volume = "207",
pages = "23--28",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Elsevier Science B.V., Amsterdam.",
number = "1",

}

TY - JOUR

T1 - Atherosclerosis, oxidative stress and auto-antibodies in systemic lupus erythematosus and primary antiphospholipid syndrome

AU - Alves, Jose D.

AU - Ames, Paul R.J.

PY - 2003

Y1 - 2003

N2 - Overwhelming evidence spanning three decades has consistently shown that coronary artery disease is a major cause of morbidity and mortality in Systemic Lupus Erythematosus. Traditionally this was explained by abnormalities of the lipid profile induced by prolonged steroid treatment. Subsequently, antiphospholipid antibodies were presented as an additional cardiovascular risk factor. Recently, antibodies towards high-density lipoprotein and antiapolipoprotein A-I have been identified. These, together with anti-beta2 glycoprotein-1, interfere with the major antioxidant defence of patients with SLE and with primary antiphospholiqid syndrome exposing them to the atherogenic potential of enhanced oxidative stress. The present review discusses how the latter auto-antibodies, together with abnormalities of their target lipid auto-antigens, could enhance the risk of atherosclerosis in SLE and APS.

AB - Overwhelming evidence spanning three decades has consistently shown that coronary artery disease is a major cause of morbidity and mortality in Systemic Lupus Erythematosus. Traditionally this was explained by abnormalities of the lipid profile induced by prolonged steroid treatment. Subsequently, antiphospholipid antibodies were presented as an additional cardiovascular risk factor. Recently, antibodies towards high-density lipoprotein and antiapolipoprotein A-I have been identified. These, together with anti-beta2 glycoprotein-1, interfere with the major antioxidant defence of patients with SLE and with primary antiphospholiqid syndrome exposing them to the atherogenic potential of enhanced oxidative stress. The present review discusses how the latter auto-antibodies, together with abnormalities of their target lipid auto-antigens, could enhance the risk of atherosclerosis in SLE and APS.

UR - http://www.scopus.com/inward/record.url?scp=0037216946&partnerID=8YFLogxK

U2 - 10.1078/0171-2985-00215

DO - 10.1078/0171-2985-00215

M3 - Review article

VL - 207

SP - 23

EP - 28

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 1

ER -